Sutep Jaruratanasirikul
6
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
100%
6 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections
Role: lead
Piperacillin/Tazobactam in Critically Ill Patients With Severe Sepsis and Septic Shock
Role: lead
The Pharmacodynamics of Meropenem in Patient With Ventilator-associated Pneumonia
Role: lead
Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units
Role: lead
The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia
Role: lead
The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia
Role: lead
All 6 trials loaded